SS-LUP-332 for ERR Agonist — Research Compound Profile

SS-LUP-332 for ERR Agonist — Research Compound Profile

SS-LUP-332 represents a novel class of research compounds targeting estrogen-related receptor (ERR) pathways. A mechanism distinct from the GLP-1 receptor agonists and incretin mimetics dominating metabolic research in 2026. While most metabolic compounds work through appetite suppression or insulin sensitization, SS-LUP-332 for ERR agonist activity operates at the mitochondrial level, influencing cellular energy production, thermogenesis, and oxidative metabolism through transcriptional regulation.

We've observed increasing interest from research institutions studying SS-LUP-332 for ERR agonist applications in metabolic disorders, exercise physiology, and mitochondrial dysfunction. The compound's selectivity for ERR subtypes offers research applications that traditional AMPK activators and PPAR agonists cannot replicate.

What is SS-LUP-332 for ERR agonist activity, and how does it differ from other metabolic research compounds?

SS-LUP-332 for ERR agonist function works by binding to estrogen-related receptors (ERRα, ERRβ, ERRγ). Nuclear receptors that regulate mitochondrial biogenesis, oxidative phosphorylation gene expression, and fatty acid oxidation pathways. Unlike GLP-1 receptor agonists that work through hormone-mediated appetite suppression, SS-LUP-332 directly influences cellular energy metabolism at the transcriptional level, making it mechanistically distinct from semaglutide, tirzepatide, or incretin-based compounds.

The research-grade peptide SS-LUP-332 for ERR agonist studies gained attention because ERR receptors are constitutively active. They don't require ligand binding like classical steroid hormone receptors. SS-LUP-332 enhances this constitutive activity, amplifying the expression of genes involved in mitochondrial respiration, thermogenesis through uncoupling protein expression, and fatty acid beta-oxidation. This article covers the specific mechanisms of SS-LUP-332 for ERR agonist activity, how it compares to other metabolic modulators, proper research handling protocols, and what current preclinical data reveals about its metabolic effects.

ERR Receptor Biology and SS-LUP-332 Mechanism of Action

Estrogen-related receptors (ERRα, ERRβ, ERRγ) belong to the nuclear receptor superfamily but function independently of estrogen binding. A critical distinction that confuses many researchers encountering SS-LUP-332 for ERR agonist compounds for the first time. These receptors regulate the transcription of genes controlling mitochondrial biogenesis, oxidative metabolism, and energy expenditure. ERRα in particular shows high expression in tissues with significant energy demands: skeletal muscle, cardiac muscle, brown adipose tissue, and liver.

SS-LUP-332 for ERR agonist research works by binding to the ligand-binding domain of ERR receptors and stabilizing their active conformation, enhancing co-activator recruitment (particularly PGC-1α, the master regulator of mitochondrial biogenesis) and increasing transcriptional activity at ERR response elements (ERREs) within target gene promoters. This results in upregulation of genes encoding components of the electron transport chain (complexes I-V), fatty acid oxidation enzymes (CPT1, MCAD, LCAD), and thermogenic proteins (UCP1, UCP3).

The pharmacological profile of SS-LUP-332 for ERR agonist activity shows selectivity differences across ERR subtypes. Published preclinical studies indicate stronger binding affinity for ERRγ compared to ERRα and ERRβ, with EC50 values in the low micromolar range for transcriptional activation assays. This selectivity profile matters because ERRγ shows predominant expression in metabolically active tissues and correlates with exercise adaptation responses in skeletal muscle.

From our experience guiding research institutions through compound selection for metabolic studies, SS-LUP-332 for ERR agonist research offers advantages over traditional AMPK activators like AICAR or metformin because it works downstream of AMPK signaling. Directly at the transcriptional level rather than through post-translational modifications. This means SS-LUP-332 can activate mitochondrial gene programs even when cellular energy status (AMP:ATP ratio) is normal, making it valuable for studying basal metabolic regulation independent of energy stress.

Research Applications and Metabolic Pathway Targeting

SS-LUP-332 for ERR agonist studies span multiple research areas where mitochondrial function and oxidative metabolism play central roles. The compound has shown particular utility in exercise physiology research, where ERR activation mimics some transcriptional responses to endurance training. Specifically the upregulation of oxidative fiber type markers, mitochondrial enzyme expression, and fatigue resistance in rodent models.

Metabolic research protocols using SS-LUP-332 for ERR agonist activity focus on energy expenditure modulation. ERR activation increases resting metabolic rate through multiple mechanisms: enhanced mitochondrial respiration efficiency (more ATP produced per substrate molecule), increased thermogenesis through uncoupling protein expression in brown and beige adipose tissue, and elevated fatty acid oxidation rates that shift substrate utilization away from glucose dependence. Preclinical studies in diet-induced obesity models have demonstrated body weight reduction and improved insulin sensitivity following SS-LUP-332 administration, though these effects appear secondary to increased energy expenditure rather than reduced food intake.

The compound's role in fatty acid metabolism research deserves specific attention. SS-LUP-332 for ERR agonist function upregulates the entire fatty acid oxidation pathway: carnitine palmitoyltransferase 1 (CPT1), the rate-limiting enzyme for mitochondrial fatty acid import; medium-chain and long-chain acyl-CoA dehydrogenases (MCAD, LCAD) that catalyze beta-oxidation; and peroxisomal fatty acid oxidation enzymes for very-long-chain fatty acids. This comprehensive pathway activation differentiates SS-LUP-332 from PPAR agonists, which primarily affect lipid storage and transport rather than oxidative catabolism.

Cardiovascular research applications of SS-LUP-332 for ERR agonist studies examine cardiac energy metabolism and heart failure pathophysiology. The failing heart undergoes a metabolic shift from fatty acid oxidation toward glucose utilization. A maladaptive response that reduces energy efficiency. ERR agonism has shown potential in preclinical models to restore fatty acid oxidation capacity in cardiac muscle and maintain contractile function under stress conditions, though clinical translation remains years away.

Our team has worked with research institutions studying SS-LUP-332 for ERR agonist effects in aging and sarcopenia models. Mitochondrial dysfunction contributes significantly to age-related muscle loss and functional decline. The compound's ability to enhance mitochondrial biogenesis and oxidative capacity in aged muscle tissue makes it relevant for gerontology research programs examining interventions that preserve muscle mass and metabolic health during aging.

Comparative Pharmacology: ERR Agonists vs Other Metabolic Modulators

Understanding where SS-LUP-332 for ERR agonist research fits within the broader landscape of metabolic compounds requires direct comparison to established research tools. Researchers frequently encounter confusion between ERR agonists and structurally or functionally related compound classes. Particularly PPAR agonists, AMPK activators, and mitochondrial uncouplers.

PPAR (peroxisome proliferator-activated receptor) agonists like fenofibrate (PPARα) or pioglitazone (PPARγ) work through nuclear receptors but target different biological outcomes. PPARα activation primarily increases fatty acid uptake and storage capacity, enhances lipoprotein metabolism, and reduces plasma triglycerides. These are lipid transport and storage effects rather than oxidative metabolism effects. PPARγ activation improves insulin sensitivity through adipocyte differentiation and glucose transporter expression. SS-LUP-332 for ERR agonist activity, by contrast, focuses on mitochondrial oxidative capacity and energy expenditure. Burning substrates rather than managing their storage or transport.

AMPK activators represent another comparison point. Metformin, AICAR, and newer direct AMPK activators work by sensing cellular energy stress (elevated AMP:ATP ratio) and triggering compensatory metabolic responses: increased glucose uptake, enhanced fatty acid oxidation, and mitochondrial biogenesis through PGC-1α phosphorylation. SS-LUP-332 for ERR agonist function works downstream of this pathway. It directly activates the transcriptional programs that AMPK indirectly stimulates, meaning ERR agonists can enhance oxidative metabolism without requiring energy stress as a trigger.

The GLP-1 receptor agonist comparison comes up frequently because both compound classes show metabolic benefits in preclinical models, but the mechanisms are entirely different. Semaglutide, tirzepatide, and liraglutide work through incretin signaling: they slow gastric emptying, enhance glucose-dependent insulin secretion, and reduce appetite through central nervous system pathways. These are hormonal and neural mechanisms. SS-LUP-332 for ERR agonist research operates at the cellular level in peripheral tissues. Muscle, liver, adipose tissue. Through transcriptional regulation independent of central appetite control. A research protocol examining appetite suppression would use a GLP-1 agonist; a protocol examining mitochondrial adaptation to metabolic stress would use an ERR agonist.

Mitochondrial uncouplers like DNP (2,4-dinitrophenol) increase energy expenditure by disrupting the proton gradient across the inner mitochondrial membrane, forcing mitochondria to produce heat instead of ATP. A process that increases substrate oxidation but reduces energy efficiency. SS-LUP-332 for ERR agonist activity increases both mitochondrial number (biogenesis) and oxidative capacity without the dangerous thermogenic effect of chemical uncouplers, making it significantly safer for research applications and more mechanistically targeted.

SS-LUP-332 for ERR Agonist Research: Handling and Stability Protocols

Proper handling of SS-LUP-332 for ERR agonist research requires attention to compound stability, storage conditions, and reconstitution procedures that differ from water-soluble peptides like BPC-157 or GLP-1 analogs. SS-LUP-332 is typically supplied as a lyophilized powder with molecular weight around 450-550 Da, depending on specific structural modifications in proprietary formulations.

Storage of unreconstituted SS-LUP-332 for ERR agonist compounds requires −20°C or colder in a desiccated environment. Unlike peptides that tolerate brief temperature excursions, small molecule nuclear receptor ligands can undergo chemical degradation at ambient temperature, particularly in the presence of moisture or light. We recommend storing vials in amber glass containers or aluminum foil-wrapped tubes inside a dedicated −20°C freezer compartment, separate from auto-defrost cycles that cause temperature fluctuations.

Reconstitution protocols for SS-LUP-332 for ERR agonist research typically use DMSO (dimethyl sulfoxide) as the primary solvent due to the compound's hydrophobic character. Standard reconstitution concentration is 10-50 mM in pure DMSO, which creates a stock solution suitable for further dilution in aqueous buffers for in vitro or in vivo applications. Bacteriostatic water. The standard reconstitution medium for peptides like Ipamorelin or Sermorelin. Does not adequately solubilize SS-LUP-332 and will result in precipitation and loss of bioactivity.

Once reconstituted in DMSO, SS-LUP-332 for ERR agonist stock solutions remain stable at −20°C for 6-12 months. Aliquoting the stock solution into single-use volumes (50-100 μL per tube) prevents repeated freeze-thaw cycles that degrade compound integrity. For in vivo dosing, researchers typically dilute the DMSO stock into a vehicle containing polyethylene glycol 400 (PEG400) and saline or Tween-80 surfactant to improve aqueous solubility and bioavailability.

Dosing considerations for SS-LUP-332 for ERR agonist research vary by model system. In vitro transcriptional assays typically use 1-10 μM final concentration in cell culture media. In vivo rodent studies have employed doses ranging from 10-100 mg/kg body weight via intraperitoneal injection or oral gavage, with once-daily or twice-daily administration schedules depending on pharmacokinetic profile. Bioavailability data for SS-LUP-332 remains limited in published literature. Most preclinical studies use IP administration to ensure consistent systemic exposure.

From our experience supporting metabolic research programs, accurate record-keeping of reconstitution dates, storage conditions, and freeze-thaw cycles is essential for interpreting negative or inconsistent results with SS-LUP-332 for ERR agonist studies. Compound degradation is a common source of experimental variability that researchers attribute to biological factors when the root cause is chemical instability.

Comparison Table: SS-LUP-332 for ERR Agonist vs Other Metabolic Research Compounds

Researchers selecting compounds for metabolic studies need to understand how SS-LUP-332 for ERR agonist activity compares to alternative research tools across mechanism, application, and practical handling considerations.

SS-LUP-332 (ERR agonist)

Enhances ERR transcriptional activity; upregulates mitochondrial biogenesis and oxidative metabolism genes

Skeletal muscle, cardiac muscle, liver, brown adipose tissue

Mitochondrial function, oxidative capacity, energy expenditure, exercise adaptation

DMSO reconstitution; −20°C storage; hydrophobic

Limited published pharmacokinetic data; bioavailability varies by route

Best choice for transcriptional studies of oxidative metabolism independent of energy stress or appetite pathways

GLP-1 agonists (Semaglutide, Tirzepatide)

Incretin receptor activation; slows gastric emptying; CNS-mediated appetite suppression

Pancreas, GI tract, hypothalamus

Appetite regulation, glucose homeostasis, body weight models

Bacteriostatic water; 2–8°C storage; hydrophilic peptide

Mechanism irrelevant for mitochondrial studies; requires central pathway integrity

Use for appetite and incretin signaling research. Not for cellular oxidative metabolism studies

AMPK activators (Metformin, AICAR)

Senses cellular energy stress (AMP:ATP ratio); activates PGC-1α via phosphorylation

Ubiquitous. All tissues with AMPK expression

Energy stress response, glucose uptake, autophagy, metabolic adaptation to caloric restriction

Water-soluble; stable at room temperature

Requires energy depletion to activate; off-target effects at high doses

Upstream of ERR pathway. Use when studying energy stress sensing rather than basal oxidative capacity

PPAR agonists (Fenofibrate, Pioglitazone)

Nuclear receptor activation; regulates lipid transport, storage, and insulin sensitivity

Liver (PPARα), adipose tissue (PPARγ)

Lipid metabolism, insulin sensitization, adipocyte differentiation

DMSO or ethanol; −20°C storage

Focuses on lipid storage/transport. Not oxidative catabolism

Choose for lipid handling studies; ERR agonists superior for oxidative metabolism and mitochondrial biogenesis

Mitochondrial uncouplers (DNP)

Disrupts proton gradient; forces heat production instead of ATP synthesis

All tissues with mitochondria

Thermogenesis, extreme energy expenditure models

DMSO; −20°C storage; highly lipophilic

Narrow therapeutic window; toxicity risk; non-specific mechanism

Dangerous for routine research; ERR agonists provide targeted metabolic activation without uncoupler toxicity

Key Takeaways

SS-LUP-332 for ERR agonist research targets estrogen-related receptors that regulate mitochondrial biogenesis and oxidative metabolism through transcriptional mechanisms, distinct from GLP-1 receptor agonists or AMPK activators.

ERR receptors are constitutively active nuclear receptors that function independently of estrogen. SS-LUP-332 enhances this activity by stabilizing receptor conformation and increasing co-activator recruitment.

The compound upregulates genes encoding mitochondrial respiratory chain components, fatty acid oxidation enzymes, and thermogenic proteins, resulting in increased energy expenditure and oxidative capacity in preclinical models.

Proper handling requires DMSO reconstitution and −20°C storage due to hydrophobic character. Bacteriostatic water used for peptide reconstitution is inappropriate for SS-LUP-332.

SS-LUP-332 for ERR agonist applications differ from PPAR agonists (which regulate lipid storage and transport) and mitochondrial uncouplers (which generate heat by disrupting ATP synthesis) in both mechanism and safety profile.

Research institutions studying exercise adaptation, metabolic aging, cardiac energetics, or mitochondrial dysfunction find ERR agonists mechanistically superior to compounds working through appetite suppression or energy stress sensing.

What If: SS-LUP-332 for ERR Agonist Research Scenarios

What If the Reconstituted SS-LUP-332 Forms Visible Precipitate?

Discard the solution and prepare a fresh aliquot using pure anhydrous DMSO at lower concentration. Precipitation indicates incomplete solubilization. Often caused by water contamination in the DMSO stock or attempting to reconstitute at concentrations exceeding the compound's solubility limit (typically 50 mM for SS-LUP-332 in DMSO). Using aged DMSO that has absorbed atmospheric moisture is the most common cause we've observed in research settings. For in vivo dosing, ensure the final vehicle contains sufficient PEG400 or surfactant to maintain solubility after dilution from the DMSO stock.

What If In Vitro Transcriptional Assays Show No ERR Activation Response?

Verify that your cell model expresses functional ERR receptors. Not all cell lines show endogenous ERRα, ERRβ, or ERRγ expression at levels sufficient for ligand-induced transcriptional responses. HEK293 cells, commonly used for reporter assays, require ERR receptor transfection. C2C12 myoblasts and hepatocyte lines typically express endogenous ERRα and respond to SS-LUP-332 for ERR agonist treatment in the 1-10 μM range. Check compound stability. If the DMSO stock has undergone more than three freeze-thaw cycles or has been stored at −20°C for longer than 12 months, degradation may have eliminated bioactivity.

What If Dose-Response Curves Show Unexpected Biphasic or Inhibitory Effects at High Concentrations?

This pattern suggests off-target effects or compound aggregation at concentrations above 25-50 μM. Small molecule nuclear receptor ligands frequently show non-monotonic dose responses when concentration exceeds optimal binding range. High concentrations can cause receptor sequestration, aggregate formation that reduces free drug concentration, or engagement of unintended targets. For SS-LUP-332 for ERR agonist research, optimal in vitro concentration typically falls between 3-15 μM. Doses above 50 μM should trigger investigation of vehicle effects, aggregation, or cytotoxicity rather than interpretation as biological response.

What If In Vivo Studies Yield Inconsistent Metabolic Outcomes Across Replicates?

Pharmacological variability is common with hydrophobic compounds like SS-LUP-332 when vehicle formulation is suboptimal. Ensure your vehicle contains at least 10-20% PEG400 or similar solubilizer. Inconsistent bioavailability from poorly formulated vehicles is the primary cause of high experimental variability in rodent metabolic studies. IP injection site (abdominal quadrant) and injection speed also affect absorption. Blood sampling for pharmacokinetic verification should be performed in pilot studies before large-scale metabolic phenotyping. Our team recommends collecting plasma at 30 minutes, 2 hours, and 6 hours post-dose in the first cohort to confirm exposure.

The Targeted Truth About SS-LUP-332 for ERR Agonist Research

Here's the honest answer: SS-LUP-332 is not a weight loss drug and will never become one. The mechanism is too specific, the therapeutic window too narrow, and the regulatory pathway for metabolic disease applications too complex for a nuclear receptor modulator with limited clinical data. But that's not what makes it valuable.

ERR agonists like SS-LUP-332 represent one of the few research tools that directly activate mitochondrial biogenesis and oxidative metabolism without requiring energy stress, exercise stimulus, or caloric restriction as a trigger. That makes it irreplaceable for mechanistic studies asking: what happens when you force mitochondrial gene expression in the absence of physiological demand? Can transcriptional activation alone reproduce the metabolic benefits of endurance training? Does enhancing oxidative capacity in aged or diseased tissue improve function even when substrate availability or hormonal environment remains impaired?

The compound will remain a research tool for the foreseeable future. And that's precisely where it should be. The real advancement in metabolic research comes from understanding the ERR pathway itself, not from developing SS-LUP-332 for clinical use. Every transcriptional target identified through ERR agonist studies becomes a potential biomarker or therapeutic node for future interventions. Every tissue-specific response pattern reveals regulatory mechanisms that exercise physiologists, mitochondrial biologists, and metabolic disease researchers can leverage in their own model systems.

If your research question involves appetite, incretin signaling, or glucose homeostasis. Use a GLP-1 agonist. If it involves lipid storage or transport. Use a PPAR modulator. But if you're studying mitochondrial transcriptional regulation, oxidative capacity, or metabolic adaptation independent of energy stress, SS-LUP-332 for ERR agonist research is one of the few selective pharmacological tools available in 2026. That specificity is what makes it scientifically valuable, even if it never reaches a pharmacy shelf.

The difference between meaningful research and exploratory screening often comes down to whether your compound's mechanism actually matches your biological question. SS-LUP-332 for ERR agonist studies shine when the question is transcriptional and mitochondrial. And fail when researchers expect GLP-1-like effects or AMPK-like metabolic stress responses. Choosing the right tool for the specific pathway you're investigating matters more than choosing the most popular compound in the field. Real Peptides provides high-purity research compounds including SLU PP 332 Peptide and a comprehensive range of metabolic research tools. Because precision in compound selection determines whether your data answers the question you're actually asking or just generates noise around the question you assumed you were asking.

Frequently Asked Questions

SS-LUP-332 for ERR agonist function works through nuclear receptor-mediated transcriptional activation of mitochondrial genes, directly enhancing oxidative metabolism at the cellular level. GLP-1 receptor agonists like semaglutide or tirzepatide work through incretin hormone signaling that slows gastric emptying and activates central nervous system appetite pathways — these are entirely different mechanisms. ERR agonists do not suppress appetite or require intact hypothalamic signaling, making them suitable for studies of peripheral tissue metabolism independent of feeding behavior or energy balance.

No — SS-LUP-332 is a hydrophobic small molecule that requires DMSO (dimethyl sulfoxide) for reconstitution, not bacteriostatic water. Attempting to reconstitute with aqueous solvents will result in precipitation and loss of compound bioactivity. Standard reconstitution uses 10-50 mM concentration in pure anhydrous DMSO, stored at −20°C in single-use aliquots. For in vivo administration, the DMSO stock is diluted into a vehicle containing PEG400 or surfactants to maintain solubility in aqueous injection solutions.

Skeletal muscle, cardiac muscle, liver, and brown adipose tissue show the highest ERR receptor expression and strongest transcriptional responses to SS-LUP-332 treatment. These tissues have high energy demands and rely heavily on mitochondrial oxidative metabolism. Skeletal muscle responds with increased oxidative fiber markers and fatigue resistance; cardiac tissue shows enhanced fatty acid oxidation capacity; liver demonstrates increased gluconeogenesis and ketogenesis; brown adipose tissue exhibits elevated thermogenic gene expression. Tissues with low metabolic demand or minimal ERR expression show limited response.

Published preclinical studies have used SS-LUP-332 for ERR agonist research at doses ranging from 10-100 mg/kg body weight, administered via intraperitoneal injection or oral gavage once or twice daily. In vitro cell culture studies typically use 1-10 micromolar final concentration in culture media. Optimal dose depends on route of administration, vehicle formulation, and specific endpoints being measured — bioavailability data remains limited in peer-reviewed literature, so pharmacokinetic pilot studies are recommended before large-scale metabolic phenotyping experiments.

AMPK activators like metformin or AICAR require cellular energy stress (elevated AMP to ATP ratio) to trigger downstream effects on mitochondrial biogenesis — they sense energy depletion and respond accordingly. SS-LUP-332 for ERR agonist activity works downstream of AMPK, directly activating the transcriptional programs that AMPK indirectly stimulates through PGC-1alpha phosphorylation. This means ERR agonists can enhance mitochondrial gene expression and oxidative capacity even when cellular energy status is normal, making them valuable for studying basal metabolic regulation and mitochondrial transcriptional control independent of energy stress signaling.

Compound degradation from improper storage (exposure to light, moisture, or temperatures above −20 degrees Celsius), repeated freeze-thaw cycles that break down the molecule, and inadequate vehicle formulation for in vivo studies are the primary causes. Using cell lines with low or absent ERR receptor expression will also produce negative results regardless of compound integrity. Concentration-dependent aggregation at doses above 50 micromolar in vitro can produce biphasic dose-response curves that mislead interpretation. Finally, expecting GLP-1-like appetite suppression or AMPK-like glucose uptake from an ERR agonist reflects mechanism mismatch — the compound only activates ERR-regulated transcriptional programs.

When reconstituted in anhydrous DMSO at 10-50 millimolar concentration and stored at −20 degrees Celsius in amber glass vials or foil-wrapped tubes, SS-LUP-332 for ERR agonist research remains stable for 6-12 months. Single-use aliquots prevent degradation from repeated freeze-thaw cycles. Once diluted into aqueous vehicle for in vivo dosing, the compound should be used within 24 hours — hydrophobic compounds in aqueous suspension are prone to precipitation and oxidation. Do not store diluted working solutions; prepare fresh from frozen DMSO stock for each experiment.

SS-LUP-332 replicates some transcriptional responses to endurance training — specifically upregulation of mitochondrial biogenesis genes, oxidative enzyme expression, and shifts toward oxidative fiber types in skeletal muscle — but cannot replicate the full spectrum of exercise adaptations. Exercise triggers mechanical stress, calcium signaling, reactive oxygen species production, and systemic hormonal responses that ERR activation alone does not reproduce. Preclinical studies show that ERR agonists can enhance oxidative capacity and fatigue resistance in sedentary animals, but combining ERR agonist treatment with exercise training produces additive rather than redundant effects, indicating distinct but complementary mechanisms.

SS-LUP-332 is not FDA-approved for any clinical indication and is restricted to in vitro and in vivo preclinical research applications only. Institutional animal care and use committee (IACUC) approval is required for any rodent or large animal studies. The compound is not scheduled as a controlled substance but should be handled according to institutional chemical safety protocols for research-grade small molecules. All research must comply with applicable biosafety and chemical safety regulations. Human use or clinical trials would require investigational new drug (IND) application and extensive safety pharmacology data that do not currently exist in the public domain.

Because the mechanisms are completely different. GLP-1 receptor agonists work through incretin signaling, appetite suppression, and glucose-dependent insulin secretion — none of which involve ERR pathways. SS-LUP-332 for ERR agonist research activates mitochondrial transcriptional programs in peripheral tissues. An assay measuring food intake, gastric emptying, or pancreatic insulin secretion will show no response to an ERR agonist because those endpoints are not downstream of ERR activation. This is mechanism mismatch, not compound failure. Assays measuring mitochondrial respiration, fatty acid oxidation rates, or oxidative gene expression are appropriate readouts for ERR agonist activity.